Test Directory

Test Code
1732
Test Name
Weill-Marchesani Syndrome NGS Panel
CPT Codes
81408, 81479
Expected Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Non-Prenatal Specimens

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

Alternate Specimen Type

Fibroblasts

T-25 Flasks

2 confluent T-25 flasks, filled to capacity

Alternate Specimen Type

Saliva (Whole blood is recommended for CNV)

DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children

Follow kit instructions (www.dnagenotek.com)

Prenatal Specimens

Either specimen type below is acceptable.

Specimen Type

Containers

Volume

Cultured cells

T-25 Flasks

2 confluent T-25 flasks derived from amnio or CVS samples.

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.

Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours

Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Alternate Names
  • WMS
  • WMS1
  • WMS2
  • WMS3
Description

Weill-Marchesani syndrome (WMS) is characterized by short stature, brachydactyly, joint stiffness, and eye abnormalities including ectopia lentis, severe myopia, glaucoma, and microspherophakia. Additionally, some patients have cardiac valvular abnormalities. Weill-Marchesani syndrome 1 (WMS1; MIM 277600) is an autosomal recessive disorder caused by mutations in the ADAMTS10 gene. Weill-Marchesani syndrome 2 (WMS2; MIM 608328) is a phenotypically similar autosomal dominant disorder caused by mutations in FBN1.  A second autosomal recessive form of WMS, Weill-Marchesani syndrome 3 (WMS3; MIM 614819), is reportedly due to mutations in the LTBP2 gene. Mutations in LTBP2 appear to show variable expressivity as some affected individuals present with all the key features of WMS, while other affected individuals from the same family do not exhibit any eye findings. In addition to WMS3, mutations in LTBP2 also cause primary congenital glaucoma 3D (GLC3D; MIM 613086) and microspherophakia and/or megalocornea with ectopia lentis and with or without secondary glaucoma (MSPKA; MIM 251750).  A Weill-Marchesani-like syndrome (MIM 613195) has also been described. This autosomal recessive disorder is caused by mutations in the ADAMTS17 gene. The clinical features of individuals with Weill-Marchesani-like syndrome include short stature and the eye abnormalities associated with WMS; however, these patients do not have brachydactyly or joint stiffness.

Testing Schedule
Monday-Friday
Genes
ADAMTS10, ADAMTS17, FBN1, LTBP2
MIM
277600, 608328, 613195, 614819
Disease Group
Ophthalmology, Skeletal Disorders